Interleukin-1 targeting treatment in familial mediterranean fever: An experience of pediatric patients

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 621-624

  Başaran, Özge ^a   Uncu, Nermin ^a   Çelikel, Banu Acar ^a   Taktak, Aysel ^a   Gur G ^a   Cakar, Nilgun ^a  

^a Ankara Child Health Hematology Oncology Education and Research Hospital   (Turkey)

Author keywords

Anti IL 1 treatment; FMF; Pediatric

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; ETANERCEPT; FIBRINOGEN; INTERLEUKIN 1; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIGOUT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTHRITIS; ARTICLE; BROWN SYNDROME; CELIAC DISEASE; CHILD; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG MEGADOSE; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; EVOKED VISUAL RESPONSE; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEMALE; FEVER; GROWTH RATE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALAISE; MALE; OPTIC NEURITIS; PLEURA EFFUSION; PRIORITY JOURNAL; REMISSION; THORAX PAIN; VASCULITIS; BLOOD; CLINICAL PROTOCOL; GENETIC SCREENING; GENETICS; METABOLISM; MUTATION; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC TESTING; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1; MALE; MUTATION;

EID: 84934968985     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.987437     Document Type: Article

References (16)

1. Kallinich T, Haff ner D, Niehues T, Huss K, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119(2):e474–83.
2. Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72–6.
3. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33(4):273–82.
4. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–71.
5. Dinarello CA. Interleukin-1beta and the autoinfl ammatory diseases. N Engl J Med. 2009;360(23):2467–70.
6. Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever. Inflammation. 2014 Aug 20. [Epub ahead of print].
7. Ozçakar ZB, Yalçınkaya F, Cakar N, Acar B, Bilgiç AE, Uncu N, et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF. Eur J Pediatr. 2011;170(8):1055–7.
8. Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, Langevitz P. Clinical diff erences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998; 75(2):216–9.
9. Ozkurede VU, Franchi L. Immunology in clinic review series; focus on auto inflammatory diseases: role of inflamma somes in auto inflammatory syndromes. Clin Exp Immunol. 2012;167(3):382–90.
10. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–84.
11. Calligaris L, Marchetti F, Tommasini A, Ventura A. The effi cacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167(6):695–6.
12. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008; 75(4): 504–5.
13. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–8.
14. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70(7):1347–8.
15. Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. Am J Med Sci. 2013;346(2):137–41.
16. Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology. 2012;51(6):1041.